These results highlight semaglutides early action on decreasing major cardiovascular events, with significant benefits already evident by the first six months, and for some, even earlier, even before any major weight loss and before most patients would have been titrated to their full target dose of 2.4 mg, lead author Jorge Plutzky, MD, director of preventive cardiology with Brigham and Womens Hospital, said in a statement
Retatrutides Phase 2 trial showed 24.2% weight loss at 48 weeks for the 12mg dose
Those shifts in identity last even after the med goes away
For many people, however, they wont provide the amount of tightening desired, and the benefits they do provide can take time to become evident
The answer isn't to reach for a hammer and eliminate GLP-1 coverage entirely
A calmer, kinder way to change your relationship with food, appetite, and metabolism